Trevi Therapeutics Inc (NASDAQ: TRVI) on Tuesday, soared 6.38% from the previous trading day, before settling in for the closing price of $2.82. Within the past 52 weeks, TRVI’s price has moved between $0.97 and $4.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -67.14%. With a float of $43.76 million, this company’s outstanding shares have now reached $68.28 million.
The extent of productivity of a business whose workforce counts for 25 workers is very important to gauge. In terms of profitability, gross margin is 38.64%, operating margin of -27394.89%, and the pretax margin is -25196.59%.
Trevi Therapeutics Inc (TRVI) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Trevi Therapeutics Inc is 43.08%, while institutional ownership is 41.07%. The most recent insider transaction that took place on Sep 06 ’24, was worth 12,784. In this transaction President & CEO of this company sold 4,219 shares at a rate of $3.03, taking the stock ownership to the 213,313 shares. Before that another transaction happened on Sep 09 ’24, when Company’s President & CEO sold 1,840 for $3.04, making the entire transaction worth $5,587. This insider now owns 213,313 shares in total.
Trevi Therapeutics Inc (TRVI) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -67.14% per share during the next fiscal year.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Trevi Therapeutics Inc (TRVI) is currently performing well based on its current performance indicators. A quick ratio of 7.38 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
The latest stats from [Trevi Therapeutics Inc, TRVI] show that its last 5-days average volume of 0.65 million was superior to 0.3 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 34.25%. Additionally, its Average True Range was 0.21.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 45.67%, which indicates a significant decrease from 60.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.29% in the past 14 days, which was lower than the 63.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.13, while its 200-day Moving Average is $2.89. Now, the first resistance to watch is $3.12. This is followed by the second major resistance level at $3.25. The third major resistance level sits at $3.42. If the price goes on to break the first support level at $2.82, it is likely to go to the next support level at $2.65. Assuming the price breaks the second support level, the third support level stands at $2.52.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
Market capitalization of the company is 230.60 million based on 76,866K outstanding shares. Right now, sales total 0 K and income totals -29,070 K. The company made 0 K in profit during its latest quarter, and -13,240 K in sales during its previous quarter.
